Bio-Rad Laboratories, Inc.

Equities

BIO

US0905722072

Medical Equipment, Supplies & Distribution

Market Closed - Nyse Other stock markets 04:00:02 2024-04-26 pm EDT			5-day change	1st Jan Change
275.9 ^USD	+0.12%		-1.35%	-14.54%

Apr. 26	Bio-Rad Laboratories, Inc. Announces Executive Vice President and President Changes, Life Science Group	CI
Apr. 15	Zacks Investment Research Lowers Price Target on Bio-Rad Laboratories to $285 From $322	MT

Tranche Update on Bio-Rad Laboratories, Inc.'s Equity Buyback Plan announced on July 20, 2023.

October 27, 2023 at 04:31 pm EDT

From July 20, 2023 to September 30, 2023, the company has repurchased 58,478 shares, representing 0.2% for $21.32 million. With this, the company has completed the repurchase of 58,478 shares, representing 0.2% for $21.32 million under the buyback announced on July 20, 2023.

Latest news about Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc. Announces Executive Vice President and President Changes, Life Science Group	Apr. 26	CI
Zacks Investment Research Lowers Price Target on Bio-Rad Laboratories to $285 From $322	Apr. 15	MT
Oncocyte Corporation and Bio-Rad Laboratories, Inc. Partner on Global Launch of Transplant Assay	Apr. 11	CI
Bio-Rad Laboratories COO Andrew Last to Retire in September	Apr. 10	MT
Bio-Rad Laboratories, Inc. Announces Chief Operating Officer Andrew Last to Retire	Apr. 10	CI
RBC Trims Price Target on Bio-Rad Laboratories to $474 From $480, Keeps Outperform Rating	Apr. 08	MT
North American Morning Briefing : Focus Turns to -2-	Apr. 04	DJ
Citigroup Downgrades Bio-Rad Laboratories to Neutral From Buy, Adjusts Price Target to $365 From $400	Apr. 03	MT
Biodesix Strikes New Research Deal With Memorial Sloan Kettering Cancer Center	Mar. 25	MT
Bio-Rad Laboratories Appoints Roop Lakkaraju as CFO	Mar. 20	MT
Bio-Rad Laboratories, Inc. Appoints Roop K. Lakkaraju as Chief Financial Officer, Effective April 15, 2024	Mar. 20	CI
Bio-Rad Laboratories, Inc. Appoints Roop K. Lakkaraju as New Executive Vice President Effective April 15, 2024	Mar. 20	CI
Transcript : Bio-Rad Laboratories, Inc. Presents at Citi?s 2024 Unplugged Medtech and Life Sciences Access Day, Feb-29-2024 02:30 PM	Feb. 29
Bio-rad Laboratories Insider Sold Shares Worth $1,008,000, According to a Recent SEC Filing	Feb. 29	MT
UBS Adjusts Bio-Rad Laboratories Price Target to $420 From $395, Maintains Buy Rating	Feb. 16	MT
RBC Trims Price Target on Bio-Rad Laboratories to $480 From $484, Keeps Outperform Rating	Feb. 16	MT
Bio Rad Labs rises after posting upbeat fourth-quarter profit	Feb. 15	RE
Bio-Rad Laboratories Q4 Adjusted Earnings, Revenue Decline, Shares Rise After-Hours	Feb. 15	MT
Transcript : Bio-Rad Laboratories, Inc., Q4 2023 Earnings Call, Feb 15, 2024	Feb. 15
Earnings Flash (BIO.B) BIO-RAD LABORATORIES Posts Q4 Revenue $681.2M, vs. Street Est of $686.6M	Feb. 15	MT
Earnings Flash (BIO.B) BIO-RAD LABORATORIES Reports Q4 EPS $3.10, vs. Street Est of $2.87	Feb. 15	MT
Bio-Rad Laboratories, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 15	CI
Bio-Rad Laboratories, Inc. Appoints Norman Schwartz as Principal Financial Officer	Feb. 14	CI
Bio-Rad Laboratories, Inc. Enters into Credit Agreement	Feb. 14	CI
Slow start for Wall Street	Jan. 03

Chart Bio-Rad Laboratories, Inc.

Duration

Period

More charts

Company Profile

Bio-Rad Laboratories, Inc. is specialized in the development, manufacturing and marketing of products used in life sciences research, clinical diagnostics and analytical chemistry. Net sales break down by activity as follows: - manufacture of clinical diagnostic tests and automated test systems (51.8%). The group also offers test kits, quality control systems and related IT systems; - manufacture of reagents, equipment and instruments for biological research (48.1%): for the separation, identification and purification of chemical and biological substances (proteins, nucleic acids, bacteria, etc.) for the proteomics, genomics research, biopharmaceuticals, cell biology and food safety markets; - other (0.1%): in particular, manufacturing of analytical instruments. At the end of 2022, the Group has 16 production sites in the United States (5), Germany (3), France (2), China (2), Poland, the United Kingdom, Switzerland and Singapore. Net sales are distributed geographically as follows: the United States (41.2%), Europe (30.4%), Asia (22.8%) and other (5.6%).

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-07 - Q1 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Bio-Rad Laboratories, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

275.9 USD

Average target price

428.9 USD

Spread / Average Target

+55.43%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
BIO-RAD LABORATORIES, INC.	-14.54%	7.89B
ABBOTT LABORATORIES	-2.31%	187B
MEDTRONIC PLC	-3.20%	106B
BECTON, DICKINSON AND COMPANY	-5.04%	66.9B
DEXCOM, INC.	+0.20%	49.45B
CENCORA, INC.	+17.29%	48B
HOYA CORPORATION	+4.06%	40.84B
WEST PHARMACEUTICAL SERVICES, INC.	+2.36%	26.25B
METTLER-TOLEDO INTERNATIONAL, INC.	+2.07%	26.48B
TERUMO CORPORATION	+12.96%	24.62B

Other Medical Equipment, Supplies & Distribution